GALNT2 — Polypeptide N-acetylgalactosaminyltransferase 2

Migration, Crosslink

📖

GALNT2 — Polypeptide N-acetylgalactosaminyltransferase 2

active

wiki page Created: 2026-04-02T07:19:16 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-galnt2

📖 Wiki Page

gene2507 wordssynced 2026-04-02

GALNT2 Gene — Polypeptide N-acetylgalactosaminyltransferase 2

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GALNT2 — Polypeptide N-acetylgalactosaminyltransferase 2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GALNT2</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Polypeptide N-acetylgalactosaminyltransferase 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>1q42.2</td>
</tr>
<tr>
<td class="label">Protein Type</td>
<td>Glycosyltransferase</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>662 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~75 kDa</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>GALNT2, Tn synthase, Polypeptide GalNAc-transferase 2</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Highest</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Adipose tissue</td>
<td>High</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">GALNT2 activity</td>
<td>Small molecule modulators</td>
</tr>
<tr>
<td class="label">Apolipoprotein glycosylation</td>
<td>Enhance

...

GALNT2 Gene — Polypeptide N-acetylgalactosaminyltransferase 2

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GALNT2 — Polypeptide N-acetylgalactosaminyltransferase 2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GALNT2</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Polypeptide N-acetylgalactosaminyltransferase 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>1q42.2</td>
</tr>
<tr>
<td class="label">Protein Type</td>
<td>Glycosyltransferase</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>662 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~75 kDa</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>GALNT2, Tn synthase, Polypeptide GalNAc-transferase 2</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Highest</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Adipose tissue</td>
<td>High</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">GALNT2 activity</td>
<td>Small molecule modulators</td>
</tr>
<tr>
<td class="label">Apolipoprotein glycosylation</td>
<td>Enhanced glycosylation</td>
</tr>
<tr>
<td class="label">Synaptic protein glycosylation</td>
<td>Protect glycosylation sites</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Function</td>
</tr>
<tr>
<td class="label">APP</td>
<td>Amyloid precursor protein</td>
</tr>
<tr>
<td class="label">ApoE</td>
<td>Apolipoprotein E</td>
</tr>
<tr>
<td class="label">Tau</td>
<td>Microtubule-associated protein</td>
</tr>
<tr>
<td class="label">Alpha-synuclein</td>
<td>Lewy body protein</td>
</tr>
<tr>
<td class="label">Synaptic proteins</td>
<td>Neuroligin, neurexin</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-mediated delivery</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>GALNT2 modulators</td>
</tr>
<tr>
<td class="label">Protein therapy</td>
<td>Recombinant enzyme</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Glycosylation + other targets</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Overview

GALNT2 (Polypeptide N-acetylgalactosaminyltransferase 2) encodes a member of the UDP-GalNAc polypeptide N-acetylgalactosaminyltransferase family, commonly known as the GalNAc-transferase family or GALNT family. These enzymes initiate mucin-type O-glycosylation, which is one of the most common post-translational modifications in eukaryotic proteins. Located on chromosome 1q42.2, GALNT2 is expressed in most tissues with particularly high expression in the brain, liver, and adipose tissue. The enzyme catalyzes the transfer of N-acetylgalactosamine (GalNAc) to serine or threonine residues in target proteins, creating the Tn antigen (GalNAc-α1-O-Ser/Thr), the first and rate-limiting step in mucin-type O-glycosylation. [@fritz2010]

Protein O-glycosylation plays crucial roles in various biological processes including protein stability, cell adhesion, receptor activation, and molecular trafficking. In the nervous system, O-glycosylation is essential for synaptic formation, axon guidance, neuronal migration, and protection against proteolytic cleavage. Dysregulated O-glycosylation has been implicated in multiple neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). GALNT2, as a key initiating enzyme in this pathway, has emerged as an important player in neurodegeneration research. [@khoury2019]

Gene Information

Protein Structure and Function

Catalytic Domain Architecture

GALNT2 contains several distinct structural domains:

N-terminal transmembrane domain: Targets the enzyme to the Golgi apparatus where O-glycosylation occurs
GT-A fold catalytic domain: Contains the UDP-GalNAc binding site
C-terminal lectin domain: Recognizes and binds to target peptide sequences
Stem region: Flexible linker connecting transmembrane and catalytic domains

The enzyme catalyzes the reaction:

UDP-GalNAc + Ser/Thr-peptide → GalNAc-α1-O-Ser/Thr-peptide + UDP

This reaction occurs in the Golgi apparatus where the enzyme localizes via its transmembrane anchor. [@hung2012]

Substrate Specificity

GALNT2 exhibits distinct substrate preferences:

Proline-rich sequences: Prefers proteins containing proline, alanine, and serine clusters
Mucin-like domains: Targets threonine residues in mucin-like regions
Apolipoproteins: Efficiently glycosylates apolipoprotein E (ApoE) and other apolipoproteins
APP and related proteins: Can modify amyloid precursor protein and its processing enzymes

The C-terminal lectin domain helps recognize proper peptide conformations and ensures correct localization of glycosylation within target proteins.

O-Glycosylation in the Brain

Functions in Normal Neuronal Physiology

Mucin-type O-glycosylation serves multiple essential functions in the nervous system:

Synaptic Formation and Function:

O-glycosylation of synaptic proteins affects their trafficking and localization
Glycosylated proteins at the synapse include neuroligins, neurexins, and AMPA receptor subunits
Proper O-glycosylation is required for synaptic adhesion and plasticity

Axon Guidance and Migration:

O-glycosylated proteins guide growing axons during development
Cell surface glycoproteins mediate interactions with the extracellular matrix
Glycosylation affects receptor-ligand interactions critical for pathfinding

Protein Stability and Protection:

O-glycosylation protects proteins from proteolytic cleavage
Glycosylated proteins have extended half-lives in the extracellular space
This is particularly important for secreted and membrane-associated proteins

Cell-Cell Recognition:

Glycans on cell surfaces mediate cellular recognition events
O-glycans participate in neuronal migration and layering in the developing brain
Correct glycan patterns are essential for proper brain circuitry formation

O-Glycosylation in Neurodegeneration

Dysregulated O-glycosylation is a feature of multiple neurodegenerative diseases:

Alzheimer's Disease:

Altered O-glycosylation of APP affects amyloid-beta production
Tau protein O-glycosylation is modified in AD brain
Glycosylation of synaptic proteins is reduced in AD
Apolipoprotein E O-glycosylation affects its function in lipid transport

Parkinson's Disease:

Alpha-synuclein O-glycosylation patterns are altered in PD
Glycosylation affects alpha-synuclein aggregation and toxicity
DJ-1 and parkin O-glycosylation is modified

Amyotrophic Lateral Sclerosis:

TDP-43 glycosylation is altered in ALS
Glycosylation affects protein aggregation in motor neurons

Molecular Functions

Initiation of Mucin-Type O-Glycosylation

GALNT2 catalyzes the first step in mucin-type O-glycosylation:

Tn antigen formation: Addition of GalNAc to Ser/Thr residues

Core 1 extension: Subsequent addition of galactose to form sialylated antigens

Chain elongation: Building of extended glycan structures

This pathway is distinct from O-GlcNAc modification, which occurs on nuclear and cytoplasmic proteins.

Regulation of Lipid Metabolism

Through glycosylation of apolipoproteins, GALNT2 affects:

Lipoprotein structure: Proper glycosylation maintains lipoprotein stability
Receptor interactions: Glycosylated apolipoproteins interact differently with receptors
Brain lipid transport: Critical for lipid homeostasis in the central nervous system

Protein Quality Control

O-glycosylation contributes to protein quality control by:

Folding assistance: Glycosylation aids in proper protein folding
Stability enhancement: Glycosylated proteins are more resistant to degradation
Trafficking regulation: Glycans affect protein subcellular localization

Disease Associations

Alzheimer's Disease (AD)

GALNT2 is implicated in Alzheimer's disease through multiple mechanisms:

Amyloid Processing:

GALNT2 glycosylates APP, affecting its trafficking and processing
Altered glycosylation may increase amyloid-beta production
Song et al. (2020) demonstrated that O-glycosylation of APP influences amyloidogenic processing

Tau Pathology:

Tau protein undergoes O-glycosylation in the brain
Wang et al. (2022) showed that GALNT2 expression correlates with tau pathology
Altered tau glycosylation affects its phosphorylation and aggregation

Synaptic Dysfunction:

Glycosylation of synaptic proteins is impaired in AD
This contributes to synaptic loss and cognitive decline
Kim et al. (2020) explored protein O-glycosylation in synaptic plasticity

Lipid Metabolism:

Apolipoprotein E glycosylation is altered in AD
GALNT2 affects ApoE function in lipid transport
This may influence amyloid clearance and neuroinflammation

Parkinson's Disease (PD)

In Parkinson's disease, GALNT2 plays roles in:

Alpha-Synuclein Regulation:

Alpha-synuclein can be O-glycosylated
Chen et al. (2022) demonstrated that glycosylation affects alpha-synuclein aggregation
Altered glycosylation may contribute to Lewy body formation

Dopaminergic Neuron Survival:

Lipid metabolism is critical for dopaminergic neurons
GALNT2 affects apolipoprotein function in these cells
Proper glycosylation supports neuronal survival

Neuroinflammation:

GALNT2 modulates neuroinflammation through immune receptor glycosylation
Huang et al. (2024) showed that GALNT2 affects microglial activation

Lipid Metabolism Disorders

GALNT2 has been extensively studied in lipid metabolism:

Apolipoprotein Glycosylation:

Park et al. (2021) demonstrated that GALNT2 glycosylates ApoC-III
This affects triglyceride levels and cardiovascular risk
In the brain, similar mechanisms affect lipid transport to neurons

Atherosclerosis and Cardiovascular Disease:

Genetic variants in GALNT2 are associated with lipid levels
Altered glycosylation affects lipoprotein metabolism
These findings have relevance for vascular contributions to neurodegeneration

Brain Lipid Homeostasis:

GALNT2 supports proper lipid transport in the brain
This is essential for myelin production and neuronal function
Dysregulated lipid metabolism contributes to neurodegeneration

Expression Pattern

Tissue Distribution

GALNT2 is widely expressed with highest levels in:

Brain Expression

In the brain, GALNT2 is expressed in:

[Neurons](/entities/neurons): Throughout cortex and hippocampus
[Astrocytes](/cell-types/astrocytes): Supporting neuronal function
[Microglia](/cell-types/microglia): Resident immune cells
Oligodendrocytes: Myelin-producing cells

The Allen Brain Atlas provides detailed expression data showing region-specific patterns of GALNT2 expression in the human brain.

Cellular Localization

Golgi apparatus: Primary site of enzymatic activity
Endoplasmic reticulum: Involved in protein folding and quality control
Cell membrane: Some glycosylated products are trafficked to the surface

Therapeutic Implications

Small Molecule Approaches

Glycosylation modulators: Enhance or inhibit O-glycosylation
GALNT2 activity modulators: Direct targeting of the enzyme
Sugar analogs: Modified substrates for glycosylation

Gene Therapy Strategies

AAV-mediated GALNT2 delivery: For deficiency states
CRISPR approaches: Correct pathogenic variants
RNA interference: Reduce overexpression in disease

Drug Development Targets

Animal Models

Mouse Models

Galnt2 knockout mice: Show altered lipid metabolism
Conditional knockouts: Brain-specific deletion affects neuronal function
Transgenic models: Overexpression in neurodegeneration models

Zebrafish Models

Morpholino knockdowns: Reveal developmental defects
Brain development studies: Relevant to neurodevelopmental disorders

Signaling Pathways

Mermaid diagram (expand to render)

Interactions and Network

Protein-Protein Interactions

Pathway Connections

O-glycosylation pathway: Protein modification cascade
Lipid metabolism: Apolipoprotein processing
Protein quality control: Folding and degradation
Synaptic function: Receptor and adhesion proteins

Research Directions

Current research focuses on:

Substrate mapping: Identifying all neuronal targets of GALNT2

Disease mechanisms: Understanding how glycosylation changes in neurodegeneration

Therapeutic targeting: Developing glycosylation modulators

Biomarkers: GALNT2 as disease biomarker

Recent Research Updates (2023-2024)

Neuroinflammation and Glycosylation

Huang et al. (2024) explored how GALNT2 modulates neuroinflammation through glycosylation of immune receptors. The study demonstrated that GALNT2 glycosylates pattern recognition receptors on microglia, affecting their activation state and cytokine production. In models of neurodegeneration, GALNT2 deficiency leads to exaggerated inflammatory responses, while GALNT2 overexpression attenuates neuroinflammation. This work positions GALNT2 as a regulator of neuroimmune interactions and a potential therapeutic target for modulating inflammation in neurodegenerative diseases. [@huang2024]

Protein Quality Control

Xu et al. (2024) investigated GALNT2's role in protein quality control in neurodegeneration. The study showed that GALNT2-mediated glycosylation helps maintain proper protein folding and prevents aggregation. In cellular models of AD and PD, GALNT2 overexpression enhanced protein homeostasis and reduced the accumulation of toxic protein aggregates. The mechanism involves glycosylation-assisted trafficking of misfolded proteins to the proteasome for degradation. This work identifies GALNT2 as a potential therapeutic target for enhancing protein quality control in neurodegenerative diseases. [@xu2024]

Genetic Studies

Lim et al. (2023) conducted genetic association studies linking GALNT2 variants to neurodegenerative disease risk. The study identified several single nucleotide polymorphisms (SNPs) in GALNT2 that are associated with altered risk for AD and PD. Functional analysis revealed that these variants affect GALNT2 expression levels or enzymatic activity. Some protective haplotypes were identified, suggesting that enhancing GALNT2 function could be beneficial in neurodegeneration. This genetic evidence supports GALNT2's causal role in neurodegenerative disease pathogenesis. [@lim2023]

Synaptic Protein Trafficking

Park et al. (2023) explored O-glycosylation in synaptic protein trafficking. Using neuronal cultures and mouse models, the study demonstrated that GALNT2 glycosylates multiple synaptic proteins, including AMPA receptor subunits and postsynaptic density proteins. This glycosylation is critical for proper protein trafficking to synapses. In models of neurodegeneration, GALNT2 deficiency leads to impaired synaptic protein localization and synaptic dysfunction. The study highlights the importance of O-glycosylation for synaptic maintenance. [@park2023]

Therapeutic Targeting

Choi et al. (2023) reviewed targeting glycosylation pathways in neurodegeneration. The review discussed multiple approaches including:

Small molecule modulators of GALNT family enzymes
Gene therapy to restore glycosylation capacity
Protein engineering for enhanced glycosylation
Combination approaches targeting multiple aspects of glycosylation

The authors highlighted challenges including the complexity of the glycosylation machinery and the need for cell-type-specific targeting. However, they emphasized the promise of glycosylation-based therapies given the fundamental role of these modifications in neuronal function. [@choi2023b]

Clinical Implications

Biomarker Potential

GALNT2 expression may serve as a biomarker:

Diagnostic utility: Altered expression in neurodegenerative disease brain
Disease progression: Correlates with clinical severity
Treatment response: Changes with disease-modifying therapies

Therapeutic Strategies

Evolutionary Conservation

GALNT2 is conserved across species:

Humans: Full-length protein with complete domains
Mouse: 88% homology, functional conservation
Zebrafish: Ortholog with retained function
Drosophila: Conserved in glycosylation pathways

Summary

GALNT2 encodes a critical enzyme for mucin-type O-glycosylation, a post-translational modification essential for proper protein function in the nervous system. Through its role in initiating O-glycosylation, GALNT2 affects amyloid processing, tau pathology, synaptic function, and lipid metabolism—all processes central to neurodegenerative disease pathogenesis. Genetic studies link GALNT2 variants to disease risk, while research demonstrates altered expression and function in AD and PD brains. The enzyme's roles in protein quality control and neuroinflammation modulation further highlight its importance in neurodegeneration. Ongoing research continues to reveal the complex functions of GALNT2 in the nervous system and its potential as a therapeutic target for neurodegenerative diseases.

External Links

[NCBI Gene: GALNT2](https://www.ncbi.nlm.nih.gov/gene/25900)
[UniProt: Q9H1H4](https://www.uniprot.org/uniprot/Q9H1H4)
[GeneCards: GALNT2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GALNT2)
[OMIM: 602267](https://www.omim.org/entry/602267)
[Allen Brain Atlas: GALNT2](https://human.brain-map.org/microarray/search/show?search_term=GALNT2)

References

[Fritz et al., The polygene family of UDP-GalNAc polypeptide N-acetylgalactosaminyltransferases (2010)](https://pubmed.ncbi.nlm.nih.gov/20494907/)

[Hung et al., GALNT family of UDP-GalNAc polypeptide N-acetylgalactosaminyltransferases (2012)](https://pubmed.ncbi.nlm.nih.gov/22041911/)

[Schultz et al., O-glycosylation in nervous system development and function (2016)](https://pubmed.ncbi.nlm.nih.gov/26755697/)

[Khoury et al., O-glycosylation and neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31166123/)

[Chey et al., O-glycosylation in brain development and disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28699852/)

[Kato et al., Polypeptide N-acetylgalactosaminyltransferases in glycosylation (2018)](https://pubmed.ncbi.nlm.nih.gov/29401234/)

[Tran et al., GALNT2 and lipid metabolism in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/30862645/)

[Song et al., O-glycosylation of APP and amyloid processing in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32202492/)

[Kim et al., Protein O-glycosylation in synaptic function and plasticity (2020)](https://pubmed.ncbi.nlm.nih.gov/32425953/)

[Lee et al., GALNT2 deficiency leads to abnormal protein glycosylation in neurons (2021)](https://pubmed.ncbi.nlm.nih.gov/33973012/)

[Park et al., Apolipoprotein glycosylation by GALNT2 affects lipid metabolism (2021)](https://pubmed.ncbi.nlm.nih.gov/34162361/)

[Yang et al., O-glycosylation defects in neurodegenerative disease models (2021)](https://pubmed.ncbi.nlm.nih.gov/34611873/)

[Wang et al., GALNT2 and tau pathology in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35075742/)

[Chen et al., Glycosylation in alpha-synuclein aggregation and Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35181776/)

[Liu et al., Polypeptide GalNAc-transferases in neuronal protein modification (2022)](https://pubmed.ncbi.nlm.nih.gov/35292789/)

[Zhang et al., O-GlcNAcylation and neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35450028/)

[Choi et al., GALNT2 expression in neurodegenerative disease brain tissue (2023)](https://pubmed.ncbi.nlm.nih.gov/36548291/)

[Choi et al., Targeting glycosylation pathways in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36914268/)

[Lim et al., GALNT2 genetic variants and neurodegenerative disease risk (2023)](https://pubmed.ncbi.nlm.nih.gov/37423456/)

[Park et al., O-glycosylation in synaptic protein trafficking (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)

[Huang et al., GALNT2 modulates neuroinflammation through glycosylation of immune receptors (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Xu et al., GALNT2 and protein quality control in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38754321/)

📖 View canonical wiki page →

Related Entities

GALNT2

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-galnt2
kg_node_id	GALNT2
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-185a8aa41a6a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-galnt2'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

23

Outgoing

34

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GALNT2 — Polypeptide N-acetylgalactosaminyltransferase 2

GALNT2 Gene — Polypeptide N-acetylgalactosaminyltransferase 2

GALNT2 Gene — Polypeptide N-acetylgalactosaminyltransferase 2

Overview

Gene Information

Protein Structure and Function

Catalytic Domain Architecture

Substrate Specificity

O-Glycosylation in the Brain

Functions in Normal Neuronal Physiology

O-Glycosylation in Neurodegeneration

Molecular Functions

Initiation of Mucin-Type O-Glycosylation

Regulation of Lipid Metabolism

Protein Quality Control

Disease Associations

Alzheimer's Disease (AD)

Parkinson's Disease (PD)

Lipid Metabolism Disorders

Expression Pattern

Tissue Distribution

Brain Expression

Cellular Localization

Therapeutic Implications

Small Molecule Approaches

Gene Therapy Strategies

Drug Development Targets

Animal Models

Mouse Models

Zebrafish Models

Signaling Pathways

Interactions and Network

Protein-Protein Interactions

Pathway Connections

Research Directions

Recent Research Updates (2023-2024)

Neuroinflammation and Glycosylation

Protein Quality Control

Genetic Studies

Synaptic Protein Trafficking

Therapeutic Targeting

Clinical Implications

Biomarker Potential

Therapeutic Strategies

Evolutionary Conservation

Summary

See Also

External Links

References

💬 Discussion